Market Trends of Global Western Blotting Industry
This section covers the major market trends shaping the Western Blotting Market according to our research experts:
Disease Diagnostic Segment is Likely to be Witnessing a Healthy CAGR Over the Forecast Period
Western blot test is having a wide range of applications in medical diagnostics. For the diagnosis of diseases such as BSE (Bovine Spongiform Encephalopathy), FIV (Feline Immunodeficiency Virus), HBV (Hepatitis B Virus) infection, and Lyme Disease among others. Generally, this test is used as a confirmatory test for the above-mentioned diseases after the ELISA test is done with a positive result. For Lyme Disease, the United States Food and Drug Administration has suggested the two-tier protocol using an ELISA test initially and then the specific western blot tests for the confirmation of diagnosis if the results of ELISA are positive. Previously, western blotting was commonly done to confirm the HIV diagnosis.
The increasing prevalence of HIV, Lyme disease, and hepatitis are major fueling factors for the market growth. For instance, as per the 2021 update from Global HIV & AIDS statistics, 38.4 million people globally were living with HIV in 2021. Moreover, 1.5 million people became newly infected with HIV in 2021. A higher prevalence of such diseases causes more diagnostic tests and thus boosts market growth. Furthermore, as per the article published in 2020 under the title 'A Practical Approach to the Diagnosis of Lyme Borreliosis: From Clinical Heterogeneity to Laboratory Methods', the diagnosis of Lyme Borreliosis was presently predicated on a two-tier serology at all phases of the infection, except when erythema migrans was present, according to European and North American recommendations. The first test in the two-tier testing process was an ELISA, EIA, or VlsE/C6 test, and the second test was a Western blot/Immunoblot assay. Hence the increase in the utilization of western blotting in the diagnostic testing of diseases like Lyme disease, and HIV boosts the market growth.
Hence, owing to the significance of this test in the disease diagnosis, it is indicated that this segment is anticipated to be witnessing a healthy CAGR over the forecast period.
North America is Expected to Dominates the Western Blotting Market Over the Forecast Period
The increasing prevalence of chronic diseases and the increasing R&D investment by the pharma and biotech companies are expected to drive the growth of the studied market in North America. According to the 2022 update from CDC, six in ten Americans live with at least one chronic disease, like heart disease and stroke, cancer, or diabetes. These and other chronic diseases are the leading causes of death and disability in America. To reduce the risk and improve the quality of life, people tend to diagnose the chronic disease at the earliest and for that purpose, western blotting is likely to be used widely thereby boosting the market growth. Furthermore, in America, health care costs are up to USD 4.1 Trillion annually. Moreover, the Lyme disease-affected areas in the United States are found to be high. For instance, as per the report from 'Lyme Disease: A Continuing Concern - A FAIR Health Infographic', in 2021 Lyme disease was more found in New Jersey, Vermont, Rhode Island, Connecticut, and Maine.
Furthermore, product launches, company collaborations, and initiatives are boosting the market growth in the studied region over the forecast period. For instance, in January 2021, Bio-Rad Laboratories, a global leader in life science research and clinical diagnostic products, announced the launch of the Bio-Rad Western Blotting Learning Center, an online library that provides comprehensive resources, information, and guidance to help researchers improve their experimental western blotting (or immunoblotting) approaches to obtain high-quality data.
Hence as per the factors mentioned above, the analyzed market is predicted to grow in the North American region over the forecast period.
